Outcome of the Board meeting and declaration of results for the quarter and nine months ending 31st March, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.7 pts more than Nifty Microcap 250 and 10.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Syschem India reported a sharp jump in Q3 FY26 (quarter ended 31 Dec 2025) revenue from operations at ₹16,164 lakhs, up about 77% from ₹9,113 lakhs in the same quarter last year. Nine-month revenue rose to ₹40,632 lakhs versus ₹24,748 lakhs last year, already exceeding the full FY25 revenue of ₹38,623 lakhs. Profit after tax for the quarter stood at ₹417 lakhs (vs ₹50 lakhs a year ago), and 9M PAT swung from a marginal loss to ₹774 lakhs. The statutory auditors (Stav & Co) issued an unmodified limited review report with no qualifications. The Board also approved a revised Related Party Transactions policy to align with the latest SEBI circular, and cleared a ₹14 crore expansion of its Panchkula plant — adding new Amoxicillin and Ampicillin capacity, expanding the existing CDF (Cloxacillin/Dicloxacillin/Flucloxacillin) unit, and upgrading effluent treatment systems — to be funded via internal accruals and borrowings, with commissioning targeted by December 2026.
Strong revenue and profit growth, along with a clean auditor report and a capex-led capacity expansion, are positive signals for shareholders. The stock could see upward momentum, though the ₹14 crore expansion funded partly through borrowings warrants a watch on debt levels going forward.